Description

Promocef Powder for Solution for Injections 1g. Vial №5

Ingredients:

Each vial contains 1g of Ceftriaxone Sodium.

Dosage:

The usual adult dose is 1 to 2 grams administered once a day. Dosage may vary based on the condition being treated. It is important to follow the healthcare provider’s instructions.

Indications:

Promocef is indicated for the treatment of various bacterial infections, including respiratory tract infections, skin and soft tissue infections, urinary tract infections, and septicemia.

Contraindications:

Do not use Promocef if you are allergic to cephalosporin antibiotics. It is important to inform your healthcare provider about any allergies before starting treatment.

Directions:

Promocef is for intravenous or intramuscular use only. It should be reconstituted with the appropriate diluent as directed before administration. Follow proper aseptic techniques during preparation.

Scientific Evidence:

Promocef, containing Ceftriaxone Sodium, has been extensively studied for its efficacy in treating various bacterial infections. Research published in the Journal of Antimicrobial Chemotherapy has shown that Ceftriaxone is highly effective against a wide range of pathogens, making it a valuable choice in clinical practice.

Additional Information:

It is essential to complete the full course of treatment with Promocef as prescribed by the healthcare provider, even if symptoms improve before the course is finished. Failure to complete the full course may result in the infection not being fully treated and could lead to antibiotic resistance.

Pharmacological Effects: Ceftriaxone, the active ingredient in Promocef, works by inhibiting bacterial cell wall synthesis, leading to the death of the bacteria. It has a broad spectrum of activity, making it effective against both Gram-positive and Gram-negative bacteria.

Clinical Trials: Clinical trials have demonstrated the efficacy of Promocef in treating various infections, with favorable outcomes and a good safety profile. A study published in the International Journal of Infectious Diseases showed that Ceftriaxone was well-tolerated and effective in the treatment of community-acquired pneumonia.